Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
RESEARCH TOOLSreports
Holding SWTX?
Track your performance easily
SWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.00 - $53.92
Previous Close$35.56
Volume642.78K
Average Volume (3M)854.16K
Market Cap
$2.64B
Enterprise Value$2.26B
Total Cash (Recent Filing)$383.88M
Total Debt (Recent Filing)$7.06M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 31, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.28
Shares Outstanding74,273,027
10 Day Avg. Volume664,566
30 Day Avg. Volume854,162
Standard Deviation0.18
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.54
Price to Sales (P/S)30.64
Price to Cash Flow (P/CF)-16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.27
Enterprise Value/Gross Profit450.61
Enterprise Value/Ebitda-18.01
Forecast
1Y Price Target
$65.60Price Target Upside85.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Springworks Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMirdametinib achieved a 52% confirmed objective response rate in the pediatric population, with a median best percentage change from baseline in target tumor volume of -42%.
Market PerformanceOgsiveo posted $21M US sales in its first full quarter on the market, surpassing consensus expectations.
Regulatory ProgressMirdametinib will be eligible to receive a Priority Review Voucher (PRV), which is valued in the $100M range, if approved.
Bears Say
Development ProgramThe development program for IK-930, a TEAD1-specific inhibitor, was discontinued based on a review of clinical data.
Financial PerformanceThe company recorded a net loss of $1.18 per share.
Market ApprovalThe probability of approval for nirogacestat in combination with a BCMA-targeted agent has been lowered, delaying its market entry.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Springworks Therapeutics lowest stock price was $18.00 and its highest was $53.92 in the past 12 months.
What is Springworks Therapeutics’s market cap?
Currently, no data Available
When is Springworks Therapeutics’s upcoming earnings report date?
Springworks Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Springworks Therapeutics’s earnings last quarter?
Springworks Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$1.116 by $0.576.
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate is -$0.75.
How many shares outstanding does Springworks Therapeutics have?
Springworks Therapeutics has 74,273,026 shares outstanding.
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Springworks Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$1.116. Following the earnings report the stock price went up 2.137%.
Which hedge fund is a major shareholder of Springworks Therapeutics?
Among the largest hedge funds holding Springworks Therapeutics’s share is Maverick Capital ltd. It holds Springworks Therapeutics’s shares valued at 98M.
---
Springworks Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.60 (85.21% Upside)
$65.60 (85.21% Upside)
Blogger Sentiment
Neutral
SWTX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 276.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.00%
12-Months-Change
Fundamentals
Return on Equity
-59.72%
Trailing 12-Months
Asset Growth
19.33%
Trailing 12-Months
Company Description
Springworks Therapeutics
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
---
SWTX Earnings Call
Q2 2024
0:00 / 0:00
---
SWTX Stock 12 Month Forecast
Average Price Target
$65.60
▲(85.21% Upside)
Technical Analysis
Best Analysts Covering SWTX
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+20.32%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +20.32% per trade.
---